SEC Comment Letter 0000000000-25-000323 to Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: Jan. 13, 2025 · CIK: 0001402328 · Accession: 0000000000-25-000323
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284142
Letter
January 13, 2025 Dr. Steve N. Slilaty Chief Executive Officer and Director Sunshine Biopharma Inc. 333 Las Olas Way CU4 Suite 433 Fort Lauderdale, FL 33301 Re:Sunshine Biopharma Inc. Registration Statement on Form S-3 Filed January 6, 2025 File No. 333-284142 Dear Dr. Steve N. Slilaty: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeff Cahlon, Esq.
Show Raw Text
January 13, 2025
Dr. Steve N. Slilaty
Chief Executive Officer and Director
Sunshine Biopharma Inc.
333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
Re:Sunshine Biopharma Inc.
Registration Statement on Form S-3
Filed January 6, 2025
File No. 333-284142
Dear Dr. Steve N. Slilaty:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeff Cahlon, Esq.